Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
148.21
+12.01 (8.82%)
At close: Jun 26, 2026, 4:00 PM EDT
150.99
+2.78 (1.88%)
After-hours: Jun 26, 2026, 7:37 PM EDT
Palvella Therapeutics Employees
Palvella Therapeutics had 29 employees as of December 31, 2025. The number of employees increased by 15 or 107.14% compared to the previous year.
Employees
29
Change (1Y)
15
Growth (1Y)
107.14%
Revenue / Employee
n/a
Profits / Employee
-$1,699,897
Market Cap
2.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29 | 15 | 107.14% |
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 293 |
| Kardigan | 241 |
| Precigen | 160 |
| Kodiak Sciences | 130 |
| Aurinia Pharmaceuticals | 128 |
PVLA News
- 5 days ago - FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin - TheFly
- 5 days ago - FDA Grants Rolling Review of Palvella's QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations - GlobeNewsWire
- 17 days ago - Palvella Therapeutics Transcript: AGM 2026 - Transcripts
- 18 days ago - Palvella Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA - TheFly
- 24 days ago - Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations - GlobeNewsWire
- 25 days ago - Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - GlobeNewsWire
- 4 weeks ago - Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program - TheFly